Patents by Inventor Ann-Hwee Lee

Ann-Hwee Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MULTISPECIFIC FGF21 RECEPTOR AGONISTS AND THEIR USES
    Publication number: 20220372168
    Abstract: Multispecific binding molecules (MBMs) comprising at least three antigen binding sites that bind to FGR1c, the GH1 domain of Klotho beta (“KLB”), and the GH2 domain of KLB, pharmaceutical compositions containing the MBMs, methods of using the MBMs and pharmaceutical compositions for treating metabolic diseases, nucleic acids encoding the MBMs, cells engineered to express the MBMs, and methods of producing MBMs.
    Type: Application
    Filed: May 3, 2022
    Publication date: November 24, 2022
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Yang SHEN, Ann-Hwee LEE, Chia-Yang LIN, Naga Suhasini AVVARU, Samuel DAVIS
  • N-TERMINAL scFv MULTISPECIFIC BINDING MOLECULES
    Publication number: 20220251220
    Abstract: Multispecific binding molecules (MBMs) comprising an N-terminal scFv, a first Fab and a second Fab, MBM conjugates comprising the MBMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the MBMs and MBM conjugates, methods of using the MBMs, MBM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the MBMs, cells engineered to express the MBMs, and methods of producing MBMs.
    Type: Application
    Filed: April 22, 2022
    Publication date: August 11, 2022
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Yang SHEN, Ann-Hwee LEE, Yan YANG, Chia-Yang LIN
  • N-TERMINAL scFv MULTISPECIFIC BINDING MOLECULES
    Publication number: 20210130477
    Abstract: Multispecific binding molecules (MBMs) comprising an N-terminal scFv, a first Fab and a second Fab, MBM conjugates comprising the MBMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the MBMs and MBM conjugates, methods of using the MBMs, MBM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the MBMs, cells engineered to express the MBMs, and methods of producing MBMs.
    Type: Application
    Filed: November 4, 2020
    Publication date: May 6, 2021
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Yang SHEN, Ann-Hwee LEE, Yan YANG, Chia-Yang LIN
  • Methods for modulating de novo hepatic lipogenesis by modulating XBP-1 activity
    Patent number: 8940479
    Abstract: The invention provides methods and compositions for modulating the expression, processing, post-translational modification, stability and/or activity of XBP-1 protein, or a protein in a signal transduction pathway involving XBP-I to treat dyslipidemias and steatosis disorders. The present invention also pertains to methods for identifying compounds that modulate the expression, processing, post-translational modification, and/or activity of XBP-I protein or a molecule in a signal transduction pathway involving XBP-1.
    Type: Grant
    Filed: January 14, 2009
    Date of Patent: January 27, 2015
    Assignee: Cornell University
    Inventors: Ann-Hwee Lee, Laurie H. Glimcher
  • Methods for modulating de novo hepatic lipogenesis by modulating XBP-1 activity
    Patent number: 8227184
    Abstract: The invention provides methods and compositions for modulating the expression, processing, post-translational modification, stability and/or activity of XBP-1 protein, or a protein in a signal transduction pathway involving XBP-1 to treat dyslipidemias and steatosis disorders. The present invention also pertains to methods for identifying compounds that modulate the expression, processing, post-translational modification, and/or activity of XBP-1 protein or a molecule in a signal transduction pathway involving XBP-1.
    Type: Grant
    Filed: January 14, 2009
    Date of Patent: July 24, 2012
    Assignee: President and Fellows of Harvard College
    Inventors: Laurie H. Glimcher, Ann-Hwee Lee
  • METHODS FOR MODULATING DE NOVO HEPATIC LIPOGENESIS BY MODULATING XBP-1 ACTIVITY
    Publication number: 20110052669
    Abstract: The invention provides methods and compositions for modulating the expression, processing, post-translational modification, stability and/or activity of XBP-1 protein, or a protein in a signal transduction pathway involving XBP-I to treat dyslipidemias and steatosis disorders. The present invention also pertains to methods for identifying compounds that modulate the expression, processing, post-translational modification, and/or activity of XBP-I protein or a molecule in a signal transduction pathway involving XBP-1.
    Type: Application
    Filed: January 14, 2009
    Publication date: March 3, 2011
    Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Ann-Hwee Lee, Laurie H. Glimcher
  • Methods for modulating de novo hepatic lipogenesis by modulating XBP-1 activity
    Publication number: 20090232738
    Abstract: The invention provides methods and compositions for modulating the expression, processing, post-translational modification, stability and/or activity of XBP-1 protein, or a protein in a signal transduction pathway involving XBP-1 to treat dyslipidemias and steatosis disorders. The present invention also pertains to methods for identifying compounds that modulate the expression, processing, post-translational modification, and/or activity of XBP-1 protein or a molecule in a signal transduction pathway involving XBP-1.
    Type: Application
    Filed: January 14, 2009
    Publication date: September 17, 2009
    Applicant: President and Fellows of Harvard College
    Inventors: Laurie H. Glimcher, Ann-Hwee Lee
  • Methods and compositions for modulating XBP-1 activity
    Publication number: 20040170622
    Abstract: The invention provides methods and compositions for modulating the expression, processing, post-translational modification, and/or activity of XBP-1 protein, or a protein in a signal transduction pathway involving XBP-1. Exemplary XBP-1 activities that can be modulated using the methods and compositions of the invention include: the Unfolded Protein Response (UPR), plasma cell differentiation, immunoglobulin production, apoptosis and the production of IL-6. The present invention also pertains to methods for identifying compounds that modulate the expression, processing, post-translational modification, and/or activity of XBP-1 protein or a molecule in a signal transduction pathway involving XBP-1.
    Type: Application
    Filed: September 2, 2003
    Publication date: September 2, 2004
    Applicant: President and Fellows of Harvard College
    Inventors: Laurie H. Glimcher, Ann-Hwee Lee, Neil Iwakoshi